Table 2.
Demographic and clinical characteristics of non-AIDS-defining cancer cases and AIDS-defining cancer cases at cancer diagnosis.
| NADC | ADC | P valuesa | |
|---|---|---|---|
| No. (%) | 115 (45.5) | 138 (54.5) | |
| Median age (years) | 48 | 38 | |
| Age (years) group [No. (%)] | |||
| <30 | 1 (0.9) | 9 (6.5) | <0.001 |
| 30–39 | 14 (12.2) | 72 (52.2) | |
| 40–49 | 53 (46.1) | 45 (32.6) | |
| ≥50 | 47 (40.9) | 12 (8.7) | |
| Median CD4 cell count (cells/μl) | 270 | 60 | |
| CD4 cell count (cells/μl) group [No. (%)] | |||
| >350 | 43 (37.4) | 20 (15.0) | <0.001 |
| 201–350 | 34 (39.6) | 14 (10.5) | |
| 51–200 | 27 (23.5) | 37 (27.8) | |
| ≤50 | 11 (9.6) | 62 (46.6) | |
| History of opportunistic infection [No. (%)]b | 65 (57.4) | 97 (70.3) | 0.033 |
| History of HAART [No. (%)] | 83 (72.2) | 93 (67.4) | 0.410 |
| Taking HAART at cancer diagnosis [No. (%)] | 68 (59.1) | 70 (50.7) | 0.181 |
| Taking HAART and HIV-1 RNA <400 copies/ml [No. (%)] | 39 (59.1) | 23 (35.4) | 0.007 |
NADC, non-AIDS-defining cancer; ADC, AIDS-defining cancer.
a
χ2 tests comparing NADC, ADC, and general cohort.
b
Defined in the Methods.